A behind-the-scenes look at ESC 2025 in Madrid
At this year’s European Society of Cardiology (ESC) Congress in Madrid, the spotlight was not only on cutting-edge research and innovation in cardiovascular medicine.
One of the highlights at the SCIRENT booth was a video interview featuring Thomas Bernd Dschietzig (MD, PhD), CEO of Relaxera and Hans-Dirk Düngen (MD, PhD), CEO of SCIRENT. Together, they introduced the upcoming SOURCE-HF phase 2 clinical trial, which investigates the therapeutic potential of Relaxin-2 in patients with heart failure – one of the most pressing conditions in cardiovascular healthcare.
The SOURCE-HF study is being initiated by Relaxera and will be supported by SCIRENT as the full-service CRO. The study will be conducted at multiple sites in countries across Europe.
A promising approach for heart failure
Relaxin-2 has shown potential as a novel therapeutic pathway in heart failure. The SOURCE-HF study aims to generate robust clinical data that could pave the way for improved treatment options and better patient outcomes.
Watch the full interview: